$1.63
0.25% yesterday
Nasdaq, Sep 27, 09:48 pm CET
ISIN
US09077B1044
Symbol
BCAB
Sector
Industry

BioAtla Inc Stock price

$1.63
-0.16 8.94% 1M
-1.83 52.89% 6M
-0.83 33.74% YTD
-0.19 10.44% 1Y
-30.17 94.87% 3Y
-16.37 90.94% 5Y
-16.37 90.94% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.00 0.00%
ISIN
US09077B1044
Symbol
BCAB
Sector
Industry

Key metrics

Market capitalization $78.79m
Enterprise Value $18.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.51
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-109.99m
Free Cash Flow (TTM) Free Cash Flow $-107.32m
Cash position $61.66m
EPS (TTM) EPS $-2.18
P/E forward negative
Short interest 10.29%
Show more

Is BioAtla Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

BioAtla Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a BioAtla Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a BioAtla Inc forecast:

Buy
100%

Financial data from BioAtla Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 1.11 1.11
6% 6%
-
-1.11 -1.11
6% 6%
-
- Selling and Administrative Expenses 22 22
10% 10%
-
- Research and Development Expense 86 86
9% 9%
-
-109 -109
9% 9%
-
- Depreciation and Amortization 1.11 1.11
6% 6%
-
EBIT (Operating Income) EBIT -110 -110
9% 9%
-
Net Profit -105 -105
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about BioAtla Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioAtla Inc Stock News

Neutral
GlobeNewsWire
5 days ago
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, ...
Neutral
Seeking Alpha
about 2 months ago
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Jay Short - Chairman, Co-Founder and CEO Richard Waldron - Chief Financial Officer Dr. Eric Sievers - Chief Medical Officer Sheri Lydick - Chief Commercial Officer Conference Call Participants Brian Cheng - JPMorgan Arthur He - H.C. Wainwright Oper...
Neutral
GlobeNewsWire
2 months ago
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today hosted a virtual R&D Day on its novel conditionally and reversibly active antibody drug conjugate mecbotamab vedotin, targeting the receptor tyrosi...
More BioAtla Inc News

Company Profile

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Jay Short
Employees 65
Founded 2007
Website www.BioAtla.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today